TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC
JOURNAL OF THORACIC ONCOLOGY（2023）
关键词
adjuvant osimertinib,non-small cell lung cancer,EGFR mutation
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要